nodes	percent_of_prediction	percent_of_DWPC	metapath
Flavoxate—PDE8A—myometrium—ovarian cancer	0.0295	0.0549	CbGeAlD
Flavoxate—PDE7A—female reproductive system—ovarian cancer	0.0275	0.0512	CbGeAlD
Flavoxate—PDE8B—uterine cervix—ovarian cancer	0.0256	0.0475	CbGeAlD
Flavoxate—PDE8A—uterine cervix—ovarian cancer	0.023	0.0427	CbGeAlD
Flavoxate—PDE8A—decidua—ovarian cancer	0.0219	0.0407	CbGeAlD
Flavoxate—PDE8B—gonad—ovarian cancer	0.0214	0.0399	CbGeAlD
Flavoxate—PDE8B—uterus—ovarian cancer	0.0213	0.0396	CbGeAlD
Flavoxate—PDE8A—endometrium—ovarian cancer	0.0208	0.0387	CbGeAlD
Flavoxate—PDE7B—testis—ovarian cancer	0.0194	0.0361	CbGeAlD
Flavoxate—PDE8A—uterus—ovarian cancer	0.0192	0.0356	CbGeAlD
Flavoxate—PDE8B—female reproductive system—ovarian cancer	0.0191	0.0356	CbGeAlD
Flavoxate—PDE4A—decidua—ovarian cancer	0.0176	0.0327	CbGeAlD
Flavoxate—PDE8B—vagina—ovarian cancer	0.0173	0.0322	CbGeAlD
Flavoxate—PDE8A—female gonad—ovarian cancer	0.0157	0.0291	CbGeAlD
Flavoxate—PDE8A—vagina—ovarian cancer	0.0156	0.029	CbGeAlD
Flavoxate—PDE8B—testis—ovarian cancer	0.0155	0.0287	CbGeAlD
Flavoxate—PDE4D—female gonad—ovarian cancer	0.0142	0.0264	CbGeAlD
Flavoxate—PDE7B—lymph node—ovarian cancer	0.0141	0.0262	CbGeAlD
Flavoxate—PDE8A—testis—ovarian cancer	0.0139	0.0258	CbGeAlD
Flavoxate—Hyperpyrexia—Paclitaxel—ovarian cancer	0.0127	0.0678	CcSEcCtD
Flavoxate—PDE4D—testis—ovarian cancer	0.0126	0.0234	CbGeAlD
Flavoxate—PDE4A—female gonad—ovarian cancer	0.0126	0.0234	CbGeAlD
Flavoxate—PDE8B—lymph node—ovarian cancer	0.0112	0.0208	CbGeAlD
Flavoxate—PDE4A—testis—ovarian cancer	0.0111	0.0207	CbGeAlD
Flavoxate—PDE4B—uterine cervix—ovarian cancer	0.011	0.0204	CbGeAlD
Flavoxate—PDE4B—decidua—ovarian cancer	0.0105	0.0195	CbGeAlD
Flavoxate—Vertigo—Altretamine—ovarian cancer	0.0102	0.0545	CcSEcCtD
Flavoxate—Leukopenia—Altretamine—ovarian cancer	0.0101	0.0543	CcSEcCtD
Flavoxate—PDE8A—lymph node—ovarian cancer	0.0101	0.0187	CbGeAlD
Flavoxate—PDE4B—endometrium—ovarian cancer	0.00994	0.0185	CbGeAlD
Flavoxate—PDE4B—gonad—ovarian cancer	0.00922	0.0171	CbGeAlD
Flavoxate—PDE4D—lymph node—ovarian cancer	0.00913	0.017	CbGeAlD
Flavoxate—PDE4B—female reproductive system—ovarian cancer	0.00824	0.0153	CbGeAlD
Flavoxate—Raloxifene—ESR1—ovarian cancer	0.0082	1	CrCbGaD
Flavoxate—PDE4A—lymph node—ovarian cancer	0.00808	0.015	CbGeAlD
Flavoxate—PDE4B—bone marrow—ovarian cancer	0.00777	0.0145	CbGeAlD
Flavoxate—PDE4B—female gonad—ovarian cancer	0.00749	0.0139	CbGeAlD
Flavoxate—PDE4B—vagina—ovarian cancer	0.00745	0.0138	CbGeAlD
Flavoxate—CHRM1—female reproductive system—ovarian cancer	0.00745	0.0138	CbGeAlD
Flavoxate—PDE4B—testis—ovarian cancer	0.00665	0.0124	CbGeAlD
Flavoxate—Vomiting—Altretamine—ovarian cancer	0.00588	0.0315	CcSEcCtD
Flavoxate—Nausea—Altretamine—ovarian cancer	0.00549	0.0294	CcSEcCtD
Flavoxate—PDE4B—lymph node—ovarian cancer	0.00482	0.00896	CbGeAlD
Flavoxate—Leukopenia—Chlorambucil—ovarian cancer	0.0036	0.0193	CcSEcCtD
Flavoxate—Confusional state—Chlorambucil—ovarian cancer	0.00331	0.0177	CcSEcCtD
Flavoxate—Leukopenia—Topotecan—ovarian cancer	0.00321	0.0172	CcSEcCtD
Flavoxate—Leukopenia—Melphalan—ovarian cancer	0.00314	0.0168	CcSEcCtD
Flavoxate—Skin disorder—Topotecan—ovarian cancer	0.00284	0.0152	CcSEcCtD
Flavoxate—Tachycardia—Melphalan—ovarian cancer	0.00279	0.015	CcSEcCtD
Flavoxate—Skin disorder—Melphalan—ovarian cancer	0.00278	0.0149	CcSEcCtD
Flavoxate—Vertigo—Vinorelbine—ovarian cancer	0.00275	0.0147	CcSEcCtD
Flavoxate—Leukopenia—Vinorelbine—ovarian cancer	0.00274	0.0147	CcSEcCtD
Flavoxate—Palpitations—Vinorelbine—ovarian cancer	0.00271	0.0145	CcSEcCtD
Flavoxate—Feeling abnormal—Chlorambucil—ovarian cancer	0.00271	0.0145	CcSEcCtD
Flavoxate—Urticaria—Chlorambucil—ovarian cancer	0.00261	0.014	CcSEcCtD
Flavoxate—Tachycardia—Vinorelbine—ovarian cancer	0.00244	0.0131	CcSEcCtD
Flavoxate—Skin disorder—Vinorelbine—ovarian cancer	0.00243	0.013	CcSEcCtD
Flavoxate—Feeling abnormal—Topotecan—ovarian cancer	0.00241	0.0129	CcSEcCtD
Flavoxate—Urticaria—Topotecan—ovarian cancer	0.00232	0.0124	CcSEcCtD
Flavoxate—Urticaria—Melphalan—ovarian cancer	0.00227	0.0122	CcSEcCtD
Flavoxate—Vomiting—Chlorambucil—ovarian cancer	0.00209	0.0112	CcSEcCtD
Flavoxate—Feeling abnormal—Vinorelbine—ovarian cancer	0.00206	0.011	CcSEcCtD
Flavoxate—Tension—Paclitaxel—ovarian cancer	0.00202	0.0108	CcSEcCtD
Flavoxate—Nervousness—Paclitaxel—ovarian cancer	0.002	0.0107	CcSEcCtD
Flavoxate—Urticaria—Vinorelbine—ovarian cancer	0.00199	0.0106	CcSEcCtD
Flavoxate—Nausea—Chlorambucil—ovarian cancer	0.00195	0.0104	CcSEcCtD
Flavoxate—Vision blurred—Paclitaxel—ovarian cancer	0.00194	0.0104	CcSEcCtD
Flavoxate—Vomiting—Topotecan—ovarian cancer	0.00186	0.00996	CcSEcCtD
Flavoxate—Vertigo—Paclitaxel—ovarian cancer	0.00185	0.00992	CcSEcCtD
Flavoxate—Leukopenia—Paclitaxel—ovarian cancer	0.00185	0.00988	CcSEcCtD
Flavoxate—Headache—Topotecan—ovarian cancer	0.00183	0.00981	CcSEcCtD
Flavoxate—Palpitations—Paclitaxel—ovarian cancer	0.00182	0.00976	CcSEcCtD
Flavoxate—Vomiting—Melphalan—ovarian cancer	0.00182	0.00975	CcSEcCtD
Flavoxate—Nausea—Topotecan—ovarian cancer	0.00174	0.0093	CcSEcCtD
Flavoxate—Dry mouth—Paclitaxel—ovarian cancer	0.00172	0.00919	CcSEcCtD
Flavoxate—Nausea—Melphalan—ovarian cancer	0.0017	0.00911	CcSEcCtD
Flavoxate—Confusional state—Paclitaxel—ovarian cancer	0.0017	0.00909	CcSEcCtD
Flavoxate—Eosinophilia—Epirubicin—ovarian cancer	0.00168	0.00897	CcSEcCtD
Flavoxate—Tachycardia—Paclitaxel—ovarian cancer	0.00164	0.00879	CcSEcCtD
Flavoxate—Skin disorder—Paclitaxel—ovarian cancer	0.00163	0.00875	CcSEcCtD
Flavoxate—Vomiting—Vinorelbine—ovarian cancer	0.00159	0.00852	CcSEcCtD
Flavoxate—Headache—Vinorelbine—ovarian cancer	0.00157	0.00839	CcSEcCtD
Flavoxate—Leukopenia—Docetaxel—ovarian cancer	0.00156	0.00838	CcSEcCtD
Flavoxate—Eosinophilia—Doxorubicin—ovarian cancer	0.00155	0.0083	CcSEcCtD
Flavoxate—Palpitations—Docetaxel—ovarian cancer	0.00154	0.00827	CcSEcCtD
Flavoxate—Drowsiness—Epirubicin—ovarian cancer	0.00151	0.00808	CcSEcCtD
Flavoxate—Somnolence—Paclitaxel—ovarian cancer	0.0015	0.00801	CcSEcCtD
Flavoxate—Nausea—Vinorelbine—ovarian cancer	0.00149	0.00796	CcSEcCtD
Flavoxate—Dry mouth—Docetaxel—ovarian cancer	0.00146	0.00779	CcSEcCtD
Flavoxate—Confusional state—Docetaxel—ovarian cancer	0.00144	0.0077	CcSEcCtD
Flavoxate—Drowsiness—Doxorubicin—ovarian cancer	0.0014	0.00747	CcSEcCtD
Flavoxate—Tachycardia—Docetaxel—ovarian cancer	0.00139	0.00745	CcSEcCtD
Flavoxate—Feeling abnormal—Paclitaxel—ovarian cancer	0.00139	0.00743	CcSEcCtD
Flavoxate—Skin disorder—Docetaxel—ovarian cancer	0.00139	0.00742	CcSEcCtD
Flavoxate—Urticaria—Paclitaxel—ovarian cancer	0.00134	0.00716	CcSEcCtD
Flavoxate—Somnolence—Docetaxel—ovarian cancer	0.00127	0.00679	CcSEcCtD
Flavoxate—Feeling abnormal—Docetaxel—ovarian cancer	0.00118	0.00629	CcSEcCtD
Flavoxate—Tension—Epirubicin—ovarian cancer	0.00116	0.00619	CcSEcCtD
Flavoxate—Nervousness—Epirubicin—ovarian cancer	0.00114	0.00613	CcSEcCtD
Flavoxate—Vision blurred—Epirubicin—ovarian cancer	0.00111	0.00595	CcSEcCtD
Flavoxate—Tension—Doxorubicin—ovarian cancer	0.00107	0.00573	CcSEcCtD
Flavoxate—Vomiting—Paclitaxel—ovarian cancer	0.00107	0.00573	CcSEcCtD
Flavoxate—Nervousness—Doxorubicin—ovarian cancer	0.00106	0.00567	CcSEcCtD
Flavoxate—Vertigo—Epirubicin—ovarian cancer	0.00106	0.00567	CcSEcCtD
Flavoxate—Leukopenia—Epirubicin—ovarian cancer	0.00106	0.00565	CcSEcCtD
Flavoxate—Headache—Paclitaxel—ovarian cancer	0.00105	0.00565	CcSEcCtD
Flavoxate—Palpitations—Epirubicin—ovarian cancer	0.00104	0.00558	CcSEcCtD
Flavoxate—Vision blurred—Doxorubicin—ovarian cancer	0.00103	0.0055	CcSEcCtD
Flavoxate—Nausea—Paclitaxel—ovarian cancer	0.001	0.00535	CcSEcCtD
Flavoxate—Dry mouth—Epirubicin—ovarian cancer	0.000982	0.00526	CcSEcCtD
Flavoxate—Vertigo—Doxorubicin—ovarian cancer	0.00098	0.00525	CcSEcCtD
Flavoxate—Leukopenia—Doxorubicin—ovarian cancer	0.000976	0.00523	CcSEcCtD
Flavoxate—Confusional state—Epirubicin—ovarian cancer	0.00097	0.00519	CcSEcCtD
Flavoxate—Palpitations—Doxorubicin—ovarian cancer	0.000964	0.00516	CcSEcCtD
Flavoxate—Tachycardia—Epirubicin—ovarian cancer	0.000939	0.00503	CcSEcCtD
Flavoxate—Skin disorder—Epirubicin—ovarian cancer	0.000934	0.005	CcSEcCtD
Flavoxate—Dry mouth—Doxorubicin—ovarian cancer	0.000908	0.00486	CcSEcCtD
Flavoxate—Vomiting—Docetaxel—ovarian cancer	0.000907	0.00486	CcSEcCtD
Flavoxate—Confusional state—Doxorubicin—ovarian cancer	0.000898	0.00481	CcSEcCtD
Flavoxate—Headache—Docetaxel—ovarian cancer	0.000894	0.00478	CcSEcCtD
Flavoxate—Tachycardia—Doxorubicin—ovarian cancer	0.000869	0.00465	CcSEcCtD
Flavoxate—Skin disorder—Doxorubicin—ovarian cancer	0.000865	0.00463	CcSEcCtD
Flavoxate—Somnolence—Epirubicin—ovarian cancer	0.000855	0.00458	CcSEcCtD
Flavoxate—Nausea—Docetaxel—ovarian cancer	0.000847	0.00454	CcSEcCtD
Flavoxate—Feeling abnormal—Epirubicin—ovarian cancer	0.000793	0.00425	CcSEcCtD
Flavoxate—Somnolence—Doxorubicin—ovarian cancer	0.000791	0.00424	CcSEcCtD
Flavoxate—Urticaria—Epirubicin—ovarian cancer	0.000764	0.00409	CcSEcCtD
Flavoxate—Feeling abnormal—Doxorubicin—ovarian cancer	0.000734	0.00393	CcSEcCtD
Flavoxate—Urticaria—Doxorubicin—ovarian cancer	0.000707	0.00379	CcSEcCtD
Flavoxate—Vomiting—Epirubicin—ovarian cancer	0.000612	0.00328	CcSEcCtD
Flavoxate—Headache—Epirubicin—ovarian cancer	0.000603	0.00323	CcSEcCtD
Flavoxate—Nausea—Epirubicin—ovarian cancer	0.000571	0.00306	CcSEcCtD
Flavoxate—Vomiting—Doxorubicin—ovarian cancer	0.000566	0.00303	CcSEcCtD
Flavoxate—Headache—Doxorubicin—ovarian cancer	0.000558	0.00299	CcSEcCtD
Flavoxate—Nausea—Doxorubicin—ovarian cancer	0.000529	0.00283	CcSEcCtD
Flavoxate—CHRM2—Signaling Pathways—YAP1—ovarian cancer	0.000107	0.000402	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CXCL8—ovarian cancer	0.000107	0.000401	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—MAPK3—ovarian cancer	0.000107	0.0004	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—XIAP—ovarian cancer	0.000107	0.000399	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—HRAS—ovarian cancer	0.000107	0.000399	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—PIK3CD—ovarian cancer	0.000106	0.000397	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—XIAP—ovarian cancer	0.000105	0.000394	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—PIK3CA—ovarian cancer	0.000105	0.000393	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CDKN1B—ovarian cancer	0.000105	0.000392	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—PIK3CA—ovarian cancer	0.000104	0.000391	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—HRAS—ovarian cancer	0.000104	0.000389	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SMARCA4—ovarian cancer	0.000104	0.000389	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—KRAS—ovarian cancer	0.000104	0.000389	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—AKT1—ovarian cancer	0.000104	0.000388	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—AKT1—ovarian cancer	0.000103	0.000385	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—AKT1—ovarian cancer	0.000103	0.000385	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CASP3—ovarian cancer	0.000103	0.000384	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SMARCA4—ovarian cancer	0.000103	0.000384	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—IL2—ovarian cancer	0.000103	0.000384	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—IL6—ovarian cancer	0.000102	0.000382	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—MAPK1—ovarian cancer	0.000102	0.000381	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—EGFR—ovarian cancer	0.000102	0.000381	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—EREG—ovarian cancer	0.000101	0.00038	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—TP53—ovarian cancer	0.000101	0.000378	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—PIK3CA—ovarian cancer	0.0001	0.000375	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—EREG—ovarian cancer	0.0001	0.000375	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CCND1—ovarian cancer	0.0001	0.000374	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—IL6—ovarian cancer	9.95e-05	0.000372	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CTNNB1—ovarian cancer	9.9e-05	0.00037	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—ERBB2—ovarian cancer	9.85e-05	0.000368	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PIK3CD—ovarian cancer	9.82e-05	0.000367	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—PIK3CA—ovarian cancer	9.73e-05	0.000364	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MTOR—ovarian cancer	9.72e-05	0.000364	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—PIK3CB—ovarian cancer	9.72e-05	0.000364	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—MMP9—ovarian cancer	9.7e-05	0.000363	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—HRAS—ovarian cancer	9.66e-05	0.000362	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—PTEN—ovarian cancer	9.65e-05	0.000361	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—KRAS—ovarian cancer	9.61e-05	0.00036	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—PIK3CA—ovarian cancer	9.55e-05	0.000357	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PGR—ovarian cancer	9.51e-05	0.000356	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—AKT1—ovarian cancer	9.41e-05	0.000352	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PGR—ovarian cancer	9.38e-05	0.000351	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—ERBB2—ovarian cancer	9.37e-05	0.000351	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CXCL8—ovarian cancer	9.34e-05	0.000349	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—HRAS—ovarian cancer	9.28e-05	0.000347	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—PIK3CB—ovarian cancer	9.25e-05	0.000346	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MTOR—ovarian cancer	9.25e-05	0.000346	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—IL6—ovarian cancer	9.25e-05	0.000346	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—AKT1—ovarian cancer	9.18e-05	0.000343	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CDKN1B—ovarian cancer	9.12e-05	0.000341	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—AKT1—ovarian cancer	9.02e-05	0.000338	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CG—ovarian cancer	8.94e-05	0.000335	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CASP3—ovarian cancer	8.94e-05	0.000334	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—IL2—ovarian cancer	8.93e-05	0.000334	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CXCL8—ovarian cancer	8.89e-05	0.000333	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—IL6—ovarian cancer	8.88e-05	0.000332	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PARP1—ovarian cancer	8.84e-05	0.000331	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—PIK3CA—ovarian cancer	8.83e-05	0.00033	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—HRAS—ovarian cancer	8.83e-05	0.00033	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CG—ovarian cancer	8.83e-05	0.00033	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PARP1—ovarian cancer	8.72e-05	0.000326	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—VEGFA—ovarian cancer	8.71e-05	0.000326	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CCND1—ovarian cancer	8.7e-05	0.000326	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CDKN1B—ovarian cancer	8.68e-05	0.000325	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—ERBB2—ovarian cancer	8.67e-05	0.000325	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—STAT3—ovarian cancer	8.63e-05	0.000323	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CTNNB1—ovarian cancer	8.62e-05	0.000322	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—NRAS—ovarian cancer	8.61e-05	0.000322	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—AKT1—ovarian cancer	8.59e-05	0.000321	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MTOR—ovarian cancer	8.56e-05	0.00032	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PIK3CB—ovarian cancer	8.56e-05	0.00032	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—AKT1—ovarian cancer	8.53e-05	0.000319	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CASP3—ovarian cancer	8.51e-05	0.000318	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—IL2—ovarian cancer	8.5e-05	0.000318	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—IL6—ovarian cancer	8.45e-05	0.000316	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—IL6ST—ovarian cancer	8.45e-05	0.000316	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MMP9—ovarian cancer	8.45e-05	0.000316	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—PTEN—ovarian cancer	8.4e-05	0.000314	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—IL6ST—ovarian cancer	8.34e-05	0.000312	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CCND1—ovarian cancer	8.28e-05	0.00031	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—MAPK3—ovarian cancer	8.24e-05	0.000308	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CXCL8—ovarian cancer	8.23e-05	0.000308	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CTNNB1—ovarian cancer	8.2e-05	0.000307	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—AKT1—ovarian cancer	8.19e-05	0.000307	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—HRAS—ovarian cancer	8.17e-05	0.000306	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CG—ovarian cancer	8.12e-05	0.000304	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MMP9—ovarian cancer	8.04e-05	0.000301	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CDKN1B—ovarian cancer	8.03e-05	0.000301	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CG—ovarian cancer	8.02e-05	0.0003	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—MYC—ovarian cancer	8.02e-05	0.0003	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—PTEN—ovarian cancer	7.99e-05	0.000299	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—AKT1—ovarian cancer	7.95e-05	0.000297	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CASP3—ovarian cancer	7.87e-05	0.000295	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CD—ovarian cancer	7.86e-05	0.000294	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—IL2—ovarian cancer	7.86e-05	0.000294	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—MAPK1—ovarian cancer	7.84e-05	0.000293	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—EGFR—ovarian cancer	7.84e-05	0.000293	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—IL6—ovarian cancer	7.82e-05	0.000293	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—AKT1—ovarian cancer	7.8e-05	0.000292	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CD—ovarian cancer	7.76e-05	0.00029	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CCND1—ovarian cancer	7.66e-05	0.000287	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CTNNB1—ovarian cancer	7.59e-05	0.000284	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—VEGFA—ovarian cancer	7.59e-05	0.000284	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—STAT3—ovarian cancer	7.51e-05	0.000281	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—NRAS—ovarian cancer	7.49e-05	0.00028	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MMP9—ovarian cancer	7.44e-05	0.000278	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—KRAS—ovarian cancer	7.41e-05	0.000277	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PTEN—ovarian cancer	7.4e-05	0.000277	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—VEGFA—ovarian cancer	7.22e-05	0.00027	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—AKT1—ovarian cancer	7.22e-05	0.00027	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MAPK3—ovarian cancer	7.18e-05	0.000268	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PPP2R1A—ovarian cancer	7.17e-05	0.000268	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—STAT3—ovarian cancer	7.15e-05	0.000267	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CD—ovarian cancer	7.14e-05	0.000267	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—NRAS—ovarian cancer	7.13e-05	0.000267	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PPP2R1A—ovarian cancer	7.08e-05	0.000265	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CD—ovarian cancer	7.05e-05	0.000264	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MYC—ovarian cancer	6.98e-05	0.000261	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CB—ovarian cancer	6.85e-05	0.000256	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MAPK3—ovarian cancer	6.83e-05	0.000256	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MAPK1—ovarian cancer	6.83e-05	0.000255	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—EGFR—ovarian cancer	6.83e-05	0.000255	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—PIK3CA—ovarian cancer	6.81e-05	0.000255	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CB—ovarian cancer	6.77e-05	0.000253	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—VEGFA—ovarian cancer	6.68e-05	0.00025	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MYC—ovarian cancer	6.64e-05	0.000249	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—STAT3—ovarian cancer	6.62e-05	0.000248	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—NRAS—ovarian cancer	6.6e-05	0.000247	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—CXCL8—ovarian cancer	6.59e-05	0.000246	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—TP53—ovarian cancer	6.58e-05	0.000246	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—CXCL8—ovarian cancer	6.5e-05	0.000243	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MAPK1—ovarian cancer	6.5e-05	0.000243	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—EGFR—ovarian cancer	6.5e-05	0.000243	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—KRAS—ovarian cancer	6.45e-05	0.000241	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MAPK3—ovarian cancer	6.32e-05	0.000236	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—HRAS—ovarian cancer	6.3e-05	0.000236	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—IL2—ovarian cancer	6.29e-05	0.000235	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CB—ovarian cancer	6.22e-05	0.000233	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—IL2—ovarian cancer	6.21e-05	0.000232	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MYC—ovarian cancer	6.15e-05	0.00023	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CB—ovarian cancer	6.14e-05	0.00023	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—KRAS—ovarian cancer	6.14e-05	0.00023	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—IL6—ovarian cancer	6.03e-05	0.000225	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MAPK1—ovarian cancer	6.01e-05	0.000225	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—EGFR—ovarian cancer	6.01e-05	0.000225	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CXCL8—ovarian cancer	5.98e-05	0.000224	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—PIK3CA—ovarian cancer	5.92e-05	0.000222	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CXCL8—ovarian cancer	5.9e-05	0.000221	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—TP53—ovarian cancer	5.73e-05	0.000214	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—IL2—ovarian cancer	5.72e-05	0.000214	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TERT—ovarian cancer	5.69e-05	0.000213	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—KRAS—ovarian cancer	5.68e-05	0.000213	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—IL2—ovarian cancer	5.64e-05	0.000211	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—PIK3CA—ovarian cancer	5.64e-05	0.000211	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TERT—ovarian cancer	5.62e-05	0.00021	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—AKT1—ovarian cancer	5.56e-05	0.000208	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—HRAS—ovarian cancer	5.48e-05	0.000205	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—TP53—ovarian cancer	5.46e-05	0.000204	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CAV1—ovarian cancer	5.27e-05	0.000197	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—IL6—ovarian cancer	5.25e-05	0.000196	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PIK3CA—ovarian cancer	5.22e-05	0.000195	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—HRAS—ovarian cancer	5.22e-05	0.000195	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CAV1—ovarian cancer	5.2e-05	0.000195	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ESR1—ovarian cancer	5.08e-05	0.00019	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—TP53—ovarian cancer	5.05e-05	0.000189	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ESR1—ovarian cancer	5.01e-05	0.000187	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—IL6—ovarian cancer	4.99e-05	0.000187	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IL6ST—ovarian cancer	4.99e-05	0.000187	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IL6ST—ovarian cancer	4.93e-05	0.000184	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—AKT1—ovarian cancer	4.84e-05	0.000181	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—HRAS—ovarian cancer	4.83e-05	0.000181	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—APC—ovarian cancer	4.8e-05	0.00018	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CG—ovarian cancer	4.8e-05	0.00018	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—NRAS—ovarian cancer	4.8e-05	0.00018	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—APC—ovarian cancer	4.74e-05	0.000177	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CG—ovarian cancer	4.74e-05	0.000177	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—NRAS—ovarian cancer	4.74e-05	0.000177	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—IL6—ovarian cancer	4.62e-05	0.000173	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—AKT1—ovarian cancer	4.61e-05	0.000172	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—MAPK3—ovarian cancer	4.6e-05	0.000172	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—MAPK3—ovarian cancer	4.54e-05	0.00017	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—MAPK1—ovarian cancer	4.37e-05	0.000164	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—EGFR—ovarian cancer	4.37e-05	0.000164	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—MAPK1—ovarian cancer	4.32e-05	0.000161	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—EGFR—ovarian cancer	4.32e-05	0.000161	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—AKT1—ovarian cancer	4.26e-05	0.000159	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CD—ovarian cancer	4.22e-05	0.000158	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CA—ovarian cancer	4.18e-05	0.000156	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CD—ovarian cancer	4.16e-05	0.000156	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—KRAS—ovarian cancer	4.13e-05	0.000155	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CA—ovarian cancer	4.12e-05	0.000154	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—KRAS—ovarian cancer	4.08e-05	0.000153	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CA—ovarian cancer	3.79e-05	0.000142	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CA—ovarian cancer	3.75e-05	0.00014	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ERBB2—ovarian cancer	3.73e-05	0.000139	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ERBB2—ovarian cancer	3.68e-05	0.000138	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MTOR—ovarian cancer	3.68e-05	0.000138	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CB—ovarian cancer	3.68e-05	0.000138	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CB—ovarian cancer	3.63e-05	0.000136	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MTOR—ovarian cancer	3.63e-05	0.000136	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CXCL8—ovarian cancer	3.53e-05	0.000132	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—HRAS—ovarian cancer	3.51e-05	0.000131	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CXCL8—ovarian cancer	3.49e-05	0.00013	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—HRAS—ovarian cancer	3.46e-05	0.00013	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CDKN1B—ovarian cancer	3.45e-05	0.000129	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—AKT1—ovarian cancer	3.41e-05	0.000128	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CDKN1B—ovarian cancer	3.41e-05	0.000127	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CASP3—ovarian cancer	3.38e-05	0.000127	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IL2—ovarian cancer	3.38e-05	0.000126	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—AKT1—ovarian cancer	3.37e-05	0.000126	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—IL6—ovarian cancer	3.36e-05	0.000126	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CASP3—ovarian cancer	3.34e-05	0.000125	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IL2—ovarian cancer	3.33e-05	0.000125	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—IL6—ovarian cancer	3.32e-05	0.000124	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCND1—ovarian cancer	3.29e-05	0.000123	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CTNNB1—ovarian cancer	3.26e-05	0.000122	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCND1—ovarian cancer	3.25e-05	0.000122	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CTNNB1—ovarian cancer	3.22e-05	0.00012	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MMP9—ovarian cancer	3.2e-05	0.00012	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PTEN—ovarian cancer	3.18e-05	0.000119	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MMP9—ovarian cancer	3.15e-05	0.000118	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PTEN—ovarian cancer	3.14e-05	0.000117	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AKT1—ovarian cancer	3.1e-05	0.000116	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AKT1—ovarian cancer	3.06e-05	0.000114	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—VEGFA—ovarian cancer	2.87e-05	0.000107	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—STAT3—ovarian cancer	2.84e-05	0.000106	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NRAS—ovarian cancer	2.83e-05	0.000106	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—VEGFA—ovarian cancer	2.83e-05	0.000106	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—STAT3—ovarian cancer	2.8e-05	0.000105	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NRAS—ovarian cancer	2.8e-05	0.000105	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MAPK3—ovarian cancer	2.71e-05	0.000102	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MAPK3—ovarian cancer	2.68e-05	0.0001	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MYC—ovarian cancer	2.64e-05	9.88e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MYC—ovarian cancer	2.61e-05	9.75e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MAPK1—ovarian cancer	2.58e-05	9.66e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—EGFR—ovarian cancer	2.58e-05	9.66e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MAPK1—ovarian cancer	2.55e-05	9.54e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—EGFR—ovarian cancer	2.55e-05	9.54e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—KRAS—ovarian cancer	2.44e-05	9.13e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—KRAS—ovarian cancer	2.41e-05	9.01e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CA—ovarian cancer	2.24e-05	8.39e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CA—ovarian cancer	2.21e-05	8.28e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TP53—ovarian cancer	2.17e-05	8.11e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TP53—ovarian cancer	2.14e-05	8.01e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HRAS—ovarian cancer	2.07e-05	7.76e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HRAS—ovarian cancer	2.05e-05	7.66e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IL6—ovarian cancer	1.98e-05	7.43e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IL6—ovarian cancer	1.96e-05	7.33e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AKT1—ovarian cancer	1.83e-05	6.85e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AKT1—ovarian cancer	1.81e-05	6.76e-05	CbGpPWpGaD
